Vyome Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HIND | VRCA | KPRX | FBIO | VYT.MC | IBO | |
|---|---|---|---|---|---|---|
| Market cap | 12.18M | 59.35M | 7.34M | 65.70M | 106.84M | 35.42M |
| P/E (TTM) | 1.0 | — | — | 0.7 | 25.8 | 0.4 |
| Forward P/E | — | -2.8 | -0.7 | -1.1 | 18.2 | — |
| Price/book | 2.0 | 13.8 | 0.6 | 0.4 | 8.2 | 3.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −70.33% | −3.49% | −26.07% | −21.77% | +111.43% | −39.34% |
| Today | −1.93% | +5.02% | −4.05% | +1.55% | −4.05% | +1.99% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HIND news ›Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering The National Law Review Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular…
Vyome Highlights VT-1953 Promise for Malignant Fungating Wound Symptoms
Posted by Defense World Staff on Oct 27th, 2026 Vyome (NASDAQ:HIND), a clinical-stage company focused on immuno-inflammatory and rare diseases, outlined its strategy for developing therapies in areas with limited treatment options,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- businesswire.com1
- natlawreview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.